LT3679016T - 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamido kietosios formos - Google Patents

2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamido kietosios formos

Info

Publication number
LT3679016T
LT3679016T LTEPPCT/US2018/049829T LTUS2018049829T LT3679016T LT 3679016 T LT3679016 T LT 3679016T LT US2018049829 T LTUS2018049829 T LT US2018049829T LT 3679016 T LT3679016 T LT 3679016T
Authority
LT
Lithuania
Prior art keywords
benzylacetamide
morpholinoethoxy
pyridin
phenyl
solid forms
Prior art date
Application number
LTEPPCT/US2018/049829T
Other languages
English (en)
Lithuanian (lt)
Inventor
Michael P. Smolinski
Original Assignee
Atnx Spv, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3679016(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv, Llc filed Critical Atnx Spv, Llc
Publication of LT3679016T publication Critical patent/LT3679016T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEPPCT/US2018/049829T 2017-09-07 2018-09-07 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamido kietosios formos LT3679016T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Publications (1)

Publication Number Publication Date
LT3679016T true LT3679016T (lt) 2026-02-10

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2018/049829T LT3679016T (lt) 2017-09-07 2018-09-07 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamido kietosios formos

Country Status (22)

Country Link
US (4) US10669236B2 (https=)
EP (2) EP4674486A3 (https=)
JP (3) JP7843116B2 (https=)
KR (2) KR102691700B1 (https=)
CN (2) CN118439992A (https=)
AU (2) AU2018330163B2 (https=)
BR (1) BR112020004419A2 (https=)
CA (1) CA3074831A1 (https=)
DK (1) DK3679016T3 (https=)
ES (1) ES3056703T3 (https=)
FI (1) FI3679016T3 (https=)
HR (1) HRP20260002T1 (https=)
IL (2) IL326637A (https=)
LT (1) LT3679016T (https=)
MX (2) MX2020002622A (https=)
PL (1) PL3679016T3 (https=)
PT (1) PT3679016T (https=)
RS (1) RS67706B1 (https=)
SG (1) SG11202001868RA (https=)
SM (1) SMT202500467T1 (https=)
TW (1) TWI815820B (https=)
WO (1) WO2019051147A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
BRPI0519424B8 (pt) 2004-12-28 2021-05-25 Athenex Inc compostos, composição e uso dos ditos compostos para a preparação de um medicamento para prevenção ou tratamento de um distúrbio de proliferação celular ou infecção microbiana
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
BRPI0605937A2 (pt) * 2005-09-13 2009-05-26 Sicor Inc processo para a sìntese de brometo de rocurÈnio
WO2008002676A2 (en) * 2006-06-29 2008-01-03 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
WO2008039421A2 (en) * 2006-09-28 2008-04-03 Merck & Co., Inc. Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7935697B2 (en) 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
JP2010527996A (ja) * 2007-05-22 2010-08-19 ウルティモルフィクス・テクノロジーズ・ベー・フェー テノホビルジソプロキシル−ヘミフマル酸共結晶
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
WO2018165647A1 (en) 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis

Also Published As

Publication number Publication date
RU2020112539A (ru) 2021-10-08
TW201920160A (zh) 2019-06-01
TWI815820B (zh) 2023-09-21
KR20240119192A (ko) 2024-08-06
EP3679016B1 (en) 2025-11-05
RU2020112539A3 (https=) 2022-04-19
US11230527B2 (en) 2022-01-25
HRP20260002T1 (hr) 2026-02-27
SG11202001868RA (en) 2020-03-30
KR102691700B1 (ko) 2024-08-02
US20250115555A1 (en) 2025-04-10
US20190071402A1 (en) 2019-03-07
AU2023201010A1 (en) 2023-03-23
JP7843116B2 (ja) 2026-04-09
PT3679016T (pt) 2025-12-05
EP4674486A3 (en) 2026-03-25
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
CN111278808B (zh) 2024-04-26
BR112020004419A2 (pt) 2020-09-08
AU2018330163B2 (en) 2023-02-02
DK3679016T3 (da) 2025-12-15
CN118439992A (zh) 2024-08-06
EP4674486A2 (en) 2026-01-07
AU2023201010B2 (en) 2024-10-03
WO2019051147A1 (en) 2019-03-14
AU2018330163A1 (en) 2020-03-26
US20200255380A1 (en) 2020-08-13
PL3679016T3 (pl) 2026-03-02
ES3056703T3 (en) 2026-02-24
CN111278808A (zh) 2020-06-12
FI3679016T3 (fi) 2025-12-12
US20220098152A1 (en) 2022-03-31
JP2020533412A (ja) 2020-11-19
MX2023001805A (es) 2023-03-13
JP2025131661A (ja) 2025-09-09
EP3679016A4 (en) 2021-09-29
IL326637A (en) 2026-04-01
US10669236B2 (en) 2020-06-02
IL272992A (en) 2020-04-30
JP2023157909A (ja) 2023-10-26
SMT202500467T1 (it) 2026-03-09
CA3074831A1 (en) 2019-03-14
MX2020002622A (es) 2020-10-01
RS67706B1 (sr) 2026-02-27
EP3679016A1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
IL280573A (en) 2-(het)aryl-substituted condensed heterocyclic derivatives as pest control agents
SG11202104206SA (en) New heterocyclic compounds
IL279910A (en) Crystal forms of 5-chloro-ene 4-[2-(dimethylphosphoryl)phenyl]-ene 2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidin-2- 4-diamine
IL247833A0 (en) 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
IL260908B (en) Substituted 2-(het)aryl-imidazolyl-carboxyamides as pest control agents
IL256237B (en) Solid forms of (z) - 4 - (5 - ((3 - benzyl - 4 - oxo - 2 - thioxothiazolidine - 5 - ylidin) methyl) furan - 2 - yl) benzoic acid
PL3658547T3 (pl) Sposób wytwarzania n-(5-(4-(4-formylo-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-yloamino)-4-metoksy-2-morfolinofenylo)akrylamidu
IL257422A (en) (s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
ZA201804482B (en) Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
SI3544976T1 (sl) Hemihidrat proste baze N-(5-(aminosulfonil)-4-metil-1,3-tiazol-2-il)-N-metil-2-(4-(2-(piridi nil)-fenil)-acetamida
ZA202003028B (en) Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
DK3559010T3 (da) Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
SG11202104883TA (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
DK3853219T3 (da) Herbicidt virksomme substituerede phenylpyrimidinhydrazider
NZ716494A (en) Processes and intermediates for the preparation of a pde10 inhibitor
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
EP3541797A4 (en) 4 - ((6- (2- (2,4-DIFLUORPHENYL) -1,1-DIFLUOR-2-HYDROXY-3- (5-MERCAPTO-1H
PL3247699T3 (pl) Sposób wytwarzania 2-[4-(cyklopropanokarbonylo)fenylo]-2-metylo-propanonitrylu
GB201806488D0 (en) Heterocyclic TADF compounds
GB201808580D0 (en) Heterocyclic compounds
UA98919U (ru) 4-этил-3-(феноксиметил)-5-((2-((5-феноксиметил)-4-фенил-4н-1,2,4-триазол-3-ил)тио)этил)тио)-4н-1,2,4-триазол, проявляющая диуретическую активность
UA97377U (en) 3 - ((2-chloroethyl) thio) -5- (3,4,5-trimethoxyphenyl) -1h-1,2,4-triazole which exhibits hypoglycemic activity